European Medicines Agency validates submission of MAA for Nidlegy
Nidlegy is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia. Both companies jointly made the following announcements:
– 23 October 2023 – Phase III PIVOTAL trial met the primary endpoint
– 31 May 2024 – Primary results of PIVOTAL presented at ASCO
– 04 June 2024 – MAA submission to EMA
The data of the Phase III Nidlegy trial are expected to be published in a peer-reviewed scientific journal in 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 04 2024 | 3:04 PM IST
Related
Beko Europe announces 1,935 redundancies: What is the group’s plan?
Beko Europe has announced the closure of two sites resulting in nearly 2,000 redundancies. ADVERTISEMENTAt a meeting in Rome with Unions at the Min
Ford to cut 4,000 jobs in Europe and Britain, cites…
Open this photo in gallery:A Ford vehicle at the Canadian International Auto Show, in Toronto, on Feb. 15.Cole Burston/ReutersFord Motor Co. F-N says it will re
European stocks fall to three-month low amid geopolitical jitters
The European markets briefly hit a three-month low due to heightened tensions in the Ukraine-Russia war. Investors shifted towards safe-haven assets, w
_w=1200_h=630.png?v=20230522122229 "Hotel booking data reveals ‘summer-holiday… | Travolution")
Hotel booking data reveals ‘summer-holiday… | Travolution
HotelHub, a hotel technology solution provider for travel management companies and their corporate customers, has released its HotelHub Index for Q3 2024.The an
